Activation of nigral and pallidal dopamine D1-like receptors modulates basal ganglia outflow in monkeys

Journal of Neurophysiology

Volumn 98, Issue 3, 2007, Pages 1489-1500

  Kliem, Michele A ^a   Maidment, Nigel T ^b   Ackerson, Larry C ^b   Chen, Sugong ^a   Smith, Yoland ^a   Wichmann, Thomas ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; MICRODIALYSIS; MICROINJECTION; NERVE CELL; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OSCILLATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; BASAL GANGLIA; BENZAZEPINES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ELECTROPHYSIOLOGY; MACACA MULATTA; MICRODIALYSIS; NEURONS; RECEPTORS, DOPAMINE D1; SUBSTANTIA NIGRA;

EID: 34548714663     PISSN: 00223077     EISSN: 15221598     Source Type: Journal    
DOI: 10.1152/jn.00171.2007     Document Type: Article

References (147)

1. Aceves J, Floran B, Sierra A, Mariscal S. D-1 receptor mediated modulation of the release of gamma-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat. Prog Neuropsychopharmacol Biol Psychiatry 19: 727-739, 1995.
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375, 1989.
3. Aldridge JW, Gilman S. The temporal structure of spike trains in the primate basal ganglia: afferent regulation of bursting demonstrated with precentral cerebral cortical ablation. Brain Res 543: 123-138, 1991.
4. Alexander GE, Crutcher MD. Serial vs. parallel processing within the primate basal ganglia-thalamocortical "motor circuit." Soc Neurosci Abstr 15: 285, 1989.
5. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13: 266-271, 1990.
6. Andersson DR, Nissbrandt H, Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 24: 617-624, 2006.
7. Ariano MA, Wang J, Noblett KL, Larson ER, Sibley DR. Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera. Brain Res 752: 26-34, 1997.
8. Arsenault MY, Parent A, Seguela P, Descarries L. Distribution and morphological characteristics of dopamine-immunoreactive neurons in the midbrain of the squirrel monkey (Saimiri sciureus). J Comp Neurol 267: 489-506, 1988.
9. Barone P, Bankiewicz KS, Corsini GU, Kopin IJ, Chase TN. Dopaminergic mechanisms in hemiparkinsonian monkeys. Neurology 37: 1592-1595, 1987.
10. Baufreton J, Garret M, Rivera A, de la Calle A, Gonon F, Dufy B, Bioulac B, Taupignon A. D5 (not D1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance. J Neurosci 23: 816-825, 2003.
11. Bergman H, Feingold A, Nini A, Raz A, Slovin H, Abeles M, Vaadia E. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 21: 32-38, 1998.
12. Bergquist F, Shahabi HN, Nissbrandt H. Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res 973: 81-91, 2003.
13. Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic PS. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 15: 7821-7836, 1995.
14. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 20: 415-455, 1973.
15. Beurrier C, Bioulac B, Hammond C. Slowly inactivating sodium current (I(NaP)) underlies single-spike activity in rat subthalamic neurons. J Neurophysiol 83: 1951-1957, 2000.
16. Beurrier C, Congar P, Bioulac B, Hammond C. Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J Neurosci 19: 599-609, 1999.
17. Bevan MD, Magill PJ, Hallworth NE, Bolam JP, Wilson CJ. Regulation of the timing and pattern of action potential generation in rat subthalamic neurons in vitro by GABA-A IPSPs. J Neurophysiol 87: 1348-1362, 2002.
18. Bjorklund A, Lindvall O. Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 83: 531-537, 1975.
19. Bogeso KP, Arnt J, Frederiksen K, Hansen HO, Hyttel J, Pedersen H. Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J Med Chem 38: 4380-4392, 1995.
20. Briggs CA, Pollock NJ, Frail DE, Paxson CL, Rakowski RF, Kang CH, Kebabian JW. Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393. Br J Pharmacol 104: 1038-1044, 1991.
21. Caille I, Dumartin B, Bloch B. Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain Res 730: 17-31, 1996.
22. Cheramy A, Leviel V, Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature 289: 537-542, 1981.
23. Choi WS, Machida CA, Ronnekleiv OK. Distribution of dopamine D1, D2, and D5 receptor mRNAs in the monkey brain: ribonuclease protection assay analysis. Brain Res Mol Brain Res 31: 86-94, 1995.
24. Ciliax BJ, Nash N, Heilman C, Sunahara R, Hartney A, Tiberi M, Rye DB, Caron MG, Niznik HB, Levey AI. Dopamine D(5) receptor immunolocalization in rat and monkey brain. Synapse 37: 125-145, 2000.
25. Clark D, White FJ. D1 dopamine receptor - the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1: 347-388, 1987.
26. Cobb WS, Abercrombie ED. Differential regulation of somatodendritic and nerve terminal dopamine release by serotonergic innervation of substantia nigra. J Neurochem 84: 576-584, 2003.
27. Crocker AD. A new view of the role of dopamine receptors in the regulation of muscle tone. Clin Exp Pharmacol Physiol 22: 846-850, 1995.
28. Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E. Central serotonin2C receptor: from physiology to pathology. Curr Top Med Chem 6: 1909-1925, 2006a.
29. Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E. Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies? Curr Med Chem 13: 3069-3081, 2006b.
30. Eberle-Wang K, Mikeladze Z, Uryu K, Chesselet MF. Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats. J Comp Neurol 384: 233-247, 1997.
31. Ferre S, O'Connor WT, Svenningsson P, Bjorklund L, Lindberg J, Tinner B, Stromberg I, Goldstein M, Ogren SO, Ungerstedt U, Fredholm BB, Fuxe K. Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat strioentopenduncular pathway and its modulation by adenosine A1 receptor-mediated mechanisms. Eur J Neurosci 8: 1545-1553, 1996.
32. Floran B, Aceves J, Sierra A, Martinez-Fong D. Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci Lett 116: 136-140, 1990.
33. Floran B, Barajas C, Floran L, Erlij D, Aceves J. Adenosine Al receptors control dopamine Dl-dependent [H-3]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. Neuroscience 115: 743-751, 2002.
34. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55: 259-272, 1996.
35. Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord 15: 1064-1069, 2000a.
36. Fox SH, Brotchie JM. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur J Pharmacol 398: 59-64, 2000b.
37. Fox SH, Moser B, Brotchie JM. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 151: 35-49, 1998.
38. Fremeau RT Jr, Duncan GE, Fornaretto MG, Dearry A, Gingrich JA, Breese GR, Caron MG. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci USA 88: 3772-3776, 1991.
39. Galvan A, Villalba RM, West SM, Maidment NT, Ackerson LC, Smith Y, Wichmann T. GABAergic modulation of the activity of globus pallidus neurons in primates: in vivo analysis of the functions of GABA receptors and GABA transporters. J Neurophysiol 94: 990-1000, 2005.
40. Garcia M, Floran B, Arias-Montano JA, Young JM, Aceves J. Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata. Neuroscience 80: 241-249, 1997.
41. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255, 1996.
42. Gatev P, Darbin O, Wichmann T. Oscillations in the basal ganglia under normal conditions and in movement disorders. Mov Disord 21: 1566-1577, 2006.
43. Geffen LB, Jessell TM, Cuello AC, Iversen LL. Release of dopamine from dendrites in rat substantia nigra. Nature 260: 258-260, 1976.
44. Gerfen CR. Dopamine receptor function in the basal ganglia. Clin Neuropharmacol 18: S162-S177, 1995.
45. Gerhardt GA, Cass WA, Huettl P, Brock S, Zhang Z, Gash DM. GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys. Brain Res 817: 163-171, 1999.
46. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80: 168-177, 2002.
47. Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Eur J Pharmacol 277: 235-241, 1995.
48. Haber SN, Fudge JL. The primate substantia nigra and VTA: integrative circuitry and function. Crit Rev Neurobiol 11: 323-342, 1997.
49. Heeringa MJ, Abercrombie ED. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J Neurochem 65: 192-200, 1995.
50. Hemsley KM, Crocker AD. Changes in muscle tone are regulated by D1 and D2 dopamine receptors in the ventral striatum and D1 receptors in the substantia nigra. Neuropsychopharmacology 25: 514-526, 2001.
51. Hollerman JR, Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci 1: 304-309, 1998.
52. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51: S2-S9, 1998.
53. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45: 19-34, 1987.
54. Hoyer D, Waeber C, Schoeffter P, Palacios JM, Dravid A. 5-HT1C receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization. Naunyn Schmiedebergs Arch Pharmacol 339: 252-258, 1989.
55. Ibanez-Sandoval O, Hernandez A, Floran B, Galarraga E, Tapia D, Valdiosera R, Erlij D, Aceves J, Bargas J. Control of the subthalamic innervation of substantia nigra pars reticulata by D-1 and D-2 dopamine receptors. J Neurophysiol 95: 1800-1811, 2006.
56. Institute for Laboratory Animal Research/Office of Laboratory Animal Welfare (ILAC/OLAW) of the National Institutes of Health. Guide for the Care and Use of Laboratory Animals (7th ed.).Washington, DC: National Research Council/National Academy Press, 1996.
57. Invernizzi RW, Pierucci M, Calcagno E, Di Giovanni G, Di Matteo V, Benigno A, Esposito E. Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 144: 1523-1535, 2007.
58. Jan C, Francois C, Tande D, Yelnik J, Tremblay L, Agid Y, Hirsch E. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur J Neurosci 12: 4525-4535, 2000.
59. Kass JI, Mintz IM. Silent plateau potentials, rhythmic bursts, and pacemaker firing: three patterns of activity that coexist in quadristable subthalamic neurons. Proc Natl Acad Sci USA 103: 183-188, 2006.
60. Khan ZU, Gutierrez A, Martin R, Penafiel A, Rivera A, de la Calle A. Dopamine D5 receptors of rat and human brain. Neuroscience 100: 689-699, 2000.
61. Kimura M. Behavioral modulation of sensory responses of primate putamen neurons. Brain Res 578: 204-214, 1992.
62. Kita H, Chiken S, Tachibana Y, Nambu A. Origins of GABA(A) and GABA(B) receptor-mediated responses of globus pallidus induced after stimulation of the putamen in the monkey. J Neurosci 26: 6554-6562, 2006.
63. Kita H, Chiken S, Tachibana Y, Nambu A. Serotonin modulates pallidal neuronal activity in the awake monkey. J Neurosci 27: 75-83, 2007.
64. Kita H, Nambu A, Kaneda K, Tachibana Y, Takada M. Role of ionotropic glutamatergic and GABAergic inputs on the firing activity of neurons in the external pallidum in awake monkeys. J Neurophysiol 92: 3069-3084, 2004.
65. Kliem MA, Paret J-F, Maxson S, Wichmann T, Smith Y. Comparative ultrastructural analysis of D1 and D5 dopamine receptor distribution in the substantia nigra and globus pallidus of normal and parkinsonian monkeys. Program No. 450.12. 2006 Abstract Viewer and Itinerary Planner. Washington, DC: Society for Neuroscience, 2006. Online.
66. Kliem MA, Wichmann T. A method to record changes in local neuronal discharge in response to infusion of small drug quantities in awake monkeys. J Neurosci Methods 138: 45-49, 2004.
67. Legendy CR, Salcman M. Bursts and recurrences of bursts in the spike trains of spontaneously active striate cortex neurons. J Neurophysiol 53: 926-939, 1985.
68. Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, Kitt CA, Price DL, Maggio R, Brann MR, Ciliax BJ, et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90: 8861-8865, 1993.
69. Levy R, Dostrovsky JO, Lang AE, Sime E, Hutchison WD, Lozano AM. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J Neurophysiol 86: 249-260, 2001.
70. Lewis MM, Watts VJ, Lawler CP, Nichols DE, Mailman RB. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Ther 286: 345-353, 1998.
71. Ljungberg T, Apicella P, Schultz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol 67: 145-163, 1992.
72. Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT. Regional distribution and cellular localization of 5-HT2C receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. Synapse 42: 12-26, 2001.
73. Marcusson J, Eriksson K. [3H]GBR-12935 binding to dopamine uptake sites in the human brain. Brain Res 457: 122-129, 1988.
74. Markstein R, Hoyer D, Engel G. 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 333: 335-341, 1986.
75. Martin LP, Waszczak BL. D1 agonist-induced excitation of substantia nigra pars reticulata neurons: mediation by D1 receptors on striatonigral terminals via a pertussis toxin-sensitive coupling pathway. J Neurosci 14: 4494-4506, 1994.
76. Matuszewich L, Yamamoto BK. Modulation of GABA release by dopamine in the substantia nigra. Synapse 32: 29-36, 1999.
77. Mayfield RD, Jones BA, Miller HA, Simosky JK, Larson GA, Zahniser NR. Modulation of endogenous GABA release by an antagonistic adenosine A(1)/dopamine D-1 receptor interaction in rat brain limbic regions but not basal ganglia. Synapse 33: 274-281, 1999.
78. Meloni EG, Davis M. The substantia nigra pars reticulata mediates the enhancement of startle by the dopamine D-1 receptor agonist SKF 82958 in rats. Psychopharmacology (Berl) 174: 228-236, 2004.
79. Mengod G, Vilaro MT, Niznik HB, Sunahara RK, Seeman P, O'Dowd BF, Palacios JM. Visualization of a dopamine D1 receptor mRNA in human and rat brain. Brain Res 10: 185-191, 1991.
80. Middleton FA, Strick PL. Basal-ganglia "projections" to the prefrontal cortex of the primate. Cereb Cortex 12: 926-935, 2002.
81. Millan MJ, Newman-Tancredi A, Quentric Y, Cussac D. The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors. Psychopharmacology (Berl) 156: 58-62, 2001.
82. Mirenowicz J, Schultz W. Importance of unpredictability for reward responses in primate dopamine neurons. J Neurophysiol 72: 1024-1027, 1994.
83. Misgeld U. Innervation of the substantia nigra. Cell Tissue Res 318: 107-114, 2004.
84. Miyazaki T, Lacey MG. Presynaptic inhibition by dopamine of a discrete component of GABA release in rat substantia nigra pars reticulate. J Physiol 513: 805-817, 1998.
85. Murer MG, Riquelme LA, Tseng KY, Pazo JH. Substantia nigra pars reticulata single unit activity in normal and 60HDA-lesioned rats: effects of intrastriatal apomorphine and subthalamic lesions. Synapse 27: 278-293, 1997.
86. Murphy NP, Maidment NT. Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. J Neurochem 73: 179-186, 1999.
87. Nakamura K, Hikosaka O. Role of dopamine in the primate caudate nucleus in reward modulation of saccades. J Neurosci 26: 5360-5369, 2006.
88. Nambu A, Llinas R. Electrophysiology of globus pallidus neurons in vitro. J Neurophysiol 72: 1127-1139, 1994.
89. Nambu A, Takada M, Inase M, Tokuno H. Dual somatotopical representations in the primate subthalamic nucleus: evidence for ordered but reversed body-map transformations from the primary motor cortex and the supplementary motor area. J Neurosci 16: 2671-2683, 1996.
90. Neijt HC, Karpf A, Schoeffter P, Engel G, Hoyer D. Characterisation of 5-HT3 recognition sites in membranes of NG 108-15 neuroblastomaglioma cells with [3H]ICS 205-930. Naunyn Schmiedebergs Arch Pharmacol 337: 493-499, 1988.
91. Neumeyer JL, Kula NS, Bergman J, Baldessarini RJ. Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol 474: 137-140, 2003.
92. Neve KA. The Dopamine Receptors. Totowa, NJ: Humana Press, 1997.
93. Nieoullon A, Cheramy A, Glowinski J. Release of dopamine evoked by electrical stimulation of the motor and visual areas of the cerebral cortex in both caudate nuclei and in the substantia nigra in the cat. Brain Res 145: 69-83, 1978.
94. Overton PG, Greenfield SA. Determinants of neuronal firing pattern in the guinea-pig subthalamic nucleus: an in vivo and in vitro comparison. J Neural Transm 10: 41-54, 1995.
95. Parent A, Cossette M. Extrastriatal dopamine and Parkinson's disease. Adv Neurol 86: 45-54, 2001.
96. Parent A, Hazrati L-N. Multiple striatal representation in primate substantia nigra. J Comp Neurol 344: 305-320, 1994.
97. Parent A, Hazrati L-N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 20: 128-154, 1995.
98. Parent A, Lavoie B, Smith Y, Bedard P. The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys. Adv Neurol 53: 111-116, 1990.
99. Pifl C, Bertel O, Schingnitz G, Hornykiewicz O. Extrastriatal dopamine in symptomatic and asymptomatic Rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurochem Int 17: 263-270, 1990.
100. Radnikow G, Misgeld U. Dopamine D1 receptors facilitate GABAA synaptic currents in the rat substantia nigra pars reticulata. J Neurosci 18: 2009-2016, 1998.
101. Reubi JC, Iversen LL, Jessell TM. Dopamine selectively increases 3H-GABA release from slices of rat substantia nigra in vitro. Nature 268: 652-654, 1977.
102. Richfield EK, Young AB, Penney JB. Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys. J Comp Neurol 262: 446-463, 1987.
103. Rick CE, Stanford IM, Lacey MG. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience 69: 903-913, 1995.
104. Robertson GS, Damsma G, Fibiger HC. Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J Neurosci 11: 2209-2216, 1991a.
105. Robertson RG, Graham WC, Sambrook MA, Crossman AR. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Res 563: 278-280, 1991b.
106. Rosales MG, Martinez-Fong D, Morales R, Nunez A, Flores G, Gongora-Alfaro JL, Floran B, Aceves J. Reciprocal interaction between glutamate and dopamine in the pars reticulata of the rat substantia nigra: a microdialysis study. Neuroscience 80: 803-810, 1997.
107. Ruffieux A, Schultz W. Dopaminergic activation of reticulata neurones in the substantia nigra. Nature 285: 240-241, 1980.
108. Ruskin DN, Bergstrom DA, Kaneoke Y, Patel BN, Twery MJ, Walters JR. Multisecond oscillations in firing rate in the basal ganglia: robust modulation by dopamine receptor activation and anesthesia. J Neurophysiol 81: 2046-2055, 1999.
109. Santiago M, Westerink BH. Characterization and pharmacological responsiveness of dopamine release recorded by microdialysis in the substantia nigra of conscious rats. J Neurochem 57: 738-747, 1991.
110. Schneider JS, Dacko S. Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Brain Res 556: 292-296, 1991.
111. Schneider JS, Rothblat DS. Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats. Neuroscience 44: 421-429, 1991.
112. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol 80: 1-27, 1998.
113. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 275: 1593-1599, 1997.
114. Smith Y, Bolam JP. Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat. Brain Res 493: 160-167, 1989.
115. Smith Y, Lavoie B, Dumas J, Parent A. Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey. Brain Res 482: 381-386, 1989.
116. Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B, Wichmann T. Role of external pallidal segment in primate parkinsonism: comparison of the effects of MPTP-induced parkinsonism and lesions of the external pallidal segment. J Neurosci 24: 6417-6426, 2004.
117. Starr M. Opposing roles of dopamine D1 and D2 receptors in nigral gamma-[3H]aminobutyric acid release? J Neurochem 49: 1042-1049, 1987.
118. Starr PA, Wichmann T, van Horne C, Bakay RA. Intranigral transplantation of fetal substantia nigra allograft in the hemiparkinsonian rhesus monkey. Cell Transpl 8: 37-45, 1999.
119. Suaud-Chagny MF, Dugast C, Chergui K, Msghina M, Gonon F. Uptake of dopamine released by impulse flow in the rat mesolimbic and striatal systems in vivo. J Neurochem 65: 2603-2611, 1995.
120. Timmerman W, Abercrombie ED. Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects. Synapse 23: 280-291, 1996.
121. Timmerman W, Westerink BH. Extracellular gamma-aminobutyric acid in the substantia nigra reticulata measured by microdialysis in awake rats: effects of various stimulants. Neurosci Lett 197: 21-24, 1995.
122. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178: 440-466, 1998.
123. Trevitt JT, Carlson BB, Nowend K, Salamone JD. Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat. Psychopharmacology (Berl) 156: 32-41, 2001.
124. Trevitt T, Carlson B, Correa M, Keene A, Morales M, Salamone D. Interactions between dopamine D1 receptors and gamma-aminobutyric acid mechanisms in substantia nigra pars reticulata of the rat: neurochemical and behavioral studies. Psychopharmacology (Berl) 159: 229-237, 2002.
125. van der Heyden JA, Venema K, Korf J. Biphasic and opposite effects of dopamine and apomorphine on endogenous GABA release in the rat substantia nigra. J Neurochem 34: 119-125, 1980.
126. Waeber C, Schoeffter P, Palacios JM, Hoyer D. Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn Schmiedebergs Arch Pharmacol 337: 595-601, 1988.
127. Waelti P, Dickinson A, Schultz W. Dopamine responses comply with basic assumptions of formal learning theory. Nature 412: 43-48, 2001.
128. Wassef M, Berod A, Sotelo C. Dopaminergic dendrites in the pars reticulata of the rat substantia nigra and their striatal input. Combined immunocytochemical localization of tyrosine hydroxylase and anterograde degeneration. Neuroscience 6: 2125-2139, 1981.
129. Waszczak BL. Differential effects of D1 and D2 dopamine receptor agonists on substantia nigra pars reticulata neurons. Brain Res 513: 125-135, 1990.
130. Waszczak BL, Walters JR. Dopamine modulation of the effects of gamma-aminobutyric acid on substantia nigra pars reticulata neurons. Science 220: 218-221, 1983.
131. Waszczak BL, Walters JR. Endogenous dopamine can modulate inhibition of substantia nigra pars reticulata neurons elicited by GABA iontophoresis or striatal stimulation. J Neurosci 6: 120-126, 1986.
132. Westerink BHC, de Vries JB. The origin of extracellular GABA recorded by brain microdialysis and assayed by a simplified on-line method. Naunyn-Schmiedebergs Arch Pharmacol 339: 603-607, 1989.
133. Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 53: 206-213, 2003a.
134. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ for the REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54: 93-101, 2003b.
135. Wichmann T, Bergman H, Starr PA, Subramanian T, Watts RL, DeLong MR. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp Brain Res 125: 397-409, 1999.
136. Wichmann T, DeLong MR. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann NY Acad Sci 991: 199-213, 2003.
137. Wichmann T, Delong MR. Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron 52: 197-204, 2006.
138. Wichmann T, Kliem MA, Soares J. Slow oscillatory discharge in the primate basal ganglia. J Neurophysiol 87: 1145-1148, 2002.
139. Wichmann T, Soares J. Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol 95: 2120-2133, 2006.
140. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376: 572-575, 1995.
141. Windels F, Carcenac C, Poupard A, Savasta M. Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus. J Neurosci 25: 5079-5086, 2005.
142. Windels F, Kiyatkin EA. Dopamine action in the substantia nigra pars reticulata: iontophoretic studies in awake, unrestrained rats. Eur J Neurosci 24: 1385-1394, 2006.
143. Wittmann M, Marino MJ, Conn PJ. Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata. J Pharmacol Exp Ther 302: 433-441, 2002.
144. Woodward RM, Panicker MM, Miledi R. Actions of dopamine and dopaminergic drugs on cloned serotonin receptors expressed in Xenopus oocytes. Proc Natl Acad Sci USA 89: 4708-4712, 1992.
145. You ZB, Herrera-Marschitz M, Nylander I, Goiny M, O'Connor WT, Ungerstedt U, Terenius L. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis - II. Effects of dopamine D1 and D2 receptor agonists. Neuroscience 63: 427-434, 1994.
146. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65: 709-730, 1995.
147. Yurek DM, Hipkens SB. Intranigral injections of SCH 23390 inhibit amphetamine-induced rotational behavior. Brain Res 623: 56-64, 1993.